Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
High Confidence RCTPrimary source: [Open]
Outcomes summary
Randomized phase 3 trial (REDEFINE 2) evaluating CagriSema versus placebo in adults with overweight or obesity and type 2 diabetes; treatment with CagriSema resulted in superior weight loss and glycemic control compared to placebo in the studied setting, with significant improvements in HbA1c and body weight reduction.
Limitations
Generalizability depends on population and comparator; interpretation depends on studied doses, estimands, and trial duration; long-term cardiovascular outcomes require further investigation.
Notes
Primary source: PMID 40544432.